The patent for semaglutide, the active ingredient in a widely used weight loss medication, has expired this year. This expiration is expected to cause a significant drop in the drug’s price, potentially making it accessible to a much larger population. Currently a costly treatment, weight loss could become a matter of willpower and affordability for hundreds of millions. Experts predict this increased access will fundamentally change approaches to managing obesity. However, the shift also raises concerns about potential new challenges arising from widespread use. The affordability of semaglutide may reshape the pharmaceutical landscape and public health strategies related to weight management.